Topic: Biotech
Dr. Moira Gunn recaps the highlights and talks with the key players from the annual BIO 2012 conference in Boston.
Dr. Moira Gunn talks with experts, Terry Hisey and Matthew Hudes from Deliotte, about the meaning of comparative effectiveness and the term: Bio-Pharma.
Dr. Moira Gunn talks with Rick Alvarez, Vice President of Operations and Research at Selexys Pharmaceuticals, about his research into Sickle Cell Anemia.
Dr. Moira Gunn learns about how Organovo has been able to build human blood vessels from CEO, Keith Murphy.
Dr. Moira Gunn talks with Avanir Pharmaceuticals CEO, Keith Katkin about a new treatment for Pseudobulbar Affect which is causes great discomfort for stroke victims.
Dr. Moira Gunn talks about the science behind extremely pre-mature babies with BCO Pharma boss, Seamus O'Loan and then switches gears to discuss pancreatic cancer with Targovax president, Hanne Kristensen.
Dr. Moira Gunn talks with sleep experts, Bernard Pécoul Executive Director at DNDi and Yves Ribeill, CEO for Scynexis, about their work and the development of a drug for sleeping sickness.
Dr. Moria Gunn talks about the trend of building a global medical team in order to make better health care decisions with IDBS' Vice President of Corporate Development, Chris Molloy.
Dr. Moira Gunn talks first with Ann Bowering from the Venture Securities Exchange, which trades clean tech, biotech and the life sciences stock in the Asia market. Then she chats with Roger Stroud, Executive Chairman of Algae.Tec Limited, about turning algae into jet fuel.
Dr. Moira Gunn talks about nano-capsules, 100 times smaller than a blood cell, and their uses in a unique drug delivery system for cancer with the CEO of Epitarget, Esben Nilssen.
